Cefadroxil NDC 67296-2199

NDC codes

FDA NDC Directory

Product NDC (as listed)67296-2199Labeler and product segments. Claims need a package NDC.

Product NDC at billing width67296-2199Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
67296-2199-1	67296219901	14 CAPSULE in 1 BOTTLE (67296-2199-1)Marketed from Jan 31, 2007

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Cefadroxil
Generic name (nonproprietary): cefadroxil
Active ingredients: Cefadroxil — 500 mg/1
Dosage form: Capsule
Route: Oral
Labeler: Redpharm Drug
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 065282
Marketing start: Jan 31, 2007
Listing expires: Dec 31, 2026
Other FDA classes: Cephalosporins (Chemical structure)
Identifiers: Product ID 67296-2199_45ac01b1-b5b8-6fc1-e063-6394a90a271aSPL ID 45ac01b1-b5b8-6fc1-e063-6394a90a271aSPL set ID 45ac01b1-b5b7-6fc1-e063-6394a90a271aRxCUI 309049UNII 280111G160
Pharmacologic class: Cephalosporin Antibacterial

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N467296219901 followed by a unit qualifier and the quantity

Package 67296-2199-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 11, 2025.

Indications (excerpt from the label)

INDICATIONS AND USAGE Cefadroxil capsules are indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: Urinary tract infections caused by E. coli , P. mirabilis , and Klebsiella species. Skin and skin structure infections caused by staphylococci and/or streptococci. Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci). Note: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefadroxil is generally effective in the eradication of streptococci from the oropharynx. However, data establ…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 065282

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 065282
Product	Strength	Form · route	Labeler	Product NDC
Cefadroxil	Cefadroxil 500 mg/1	CapsuleOral	Teva Pharmaceuticals USA, Inc.	0093-3196